January 30, 2025
Ready to move from one-time checks to continuous validation monitoring? Our guide gives you a 7-step approach to scaling validation across your portfolio, plus how to prioritize findings using a risk-based approach.

Erin Erginer
Senior Director of Product, Certara’s Pinnacle 21Innovative leader with 20 years of clinical research and healthcare experience, specializing in acquisition, management, and transformation of clinical biospecimen and digital health assessment data. Collaborative creator of tech-enabled solutions for the pharmaceutical industry. Accomplished, analytical director possessing strong interpersonal and communication skills with experience in managing multi-functional teams at both a strategic and tactical level. Key strengths include driving transformational change, strategic planning and execution, spearheading business process improvement initiatives, and building high-performing organizations. Built and introduced countless strategies within R&D to achieve efficiencies and resolve process and application gaps. Experienced in operations oversight and guidance, including resource and financial projections and prioritization.
See how Pinnacle 21 Enterprise can revolutionize your clinical trial design process.
Automate compliance checks and validation.
Collaborate seamlessly in the cloud.
Gain insights and streamline regulatory submissions.
FAQs
How often does the FDA update its FDA validation rules for submission data?
The FDA revises its validator and business rules periodically, rather than on a fixed schedule. For example, it moved from the March 2021 version 1.5 to an updated Validator Rules V1.6 in December 2022. Because updates can change field-level checks and error/warning thresholds, teams should monitor FDA’s Study Data Standards Resources page regularly and build a review cadence for FDA validation rules in clinical data management workflows to ensure specs and validation engines stay current.
Do FDA validation rules in clinical trials apply the same way in Phase I as in later-phase studies?
Yes. The rules themselves aren’t phase-dependent, so technical conformance and business-rule checks apply regardless of study stage. What changes is volume and complexity, since Phase III datasets typically surface far more issues to reconcile. Running FDA validation rules for submission data early, even in Phase I, prevents a backlog of unresolved errors from accumulating before your first regulatory submission.
What's the difference between FDA Business Rules and FDA Validator Rules?
Business Rules cover regulatory and procedural expectations, such as consistent use of controlled terminology, and often require human judgment. Validator Rules are the FDA’s published technical rule set for checking conformance to CDISC standards and can largely be automated. Together they form the backbone of FDA validation rules for submission data. Understanding the split helps teams apply FDA validation rules in clinical data management tools more efficiently.
What happens if a dataset fails FDA validation rules in clinical trials before submission?
A failed check produces either an Error or a Warning. Errors are critical and should be resolved before submission, since unresolved errors raise the risk of delays or a Refuse-to-File outcome. Warnings don’t block submission but should not go unaddressed and should be explained in the Study Data Reviewer’s Guide. Checking against FDA validation rules for submission data before final dataset lock leaves time to correct or properly document each flagged issue.
Where can sponsors access FDA's official validation rules for submission data before they submit?
The FDA publishes its rule sets, including the Validator Rules, on its Study Data Standards Resources page, alongside the Self-Check Worksheet for Study Data Preparation and the Study Data Technical Conformance Guide. Reviewing these directly helps sponsors apply FDA validation rules in clinical data management and FDA validation rules in clinical trials consistently.


